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ABSTRACT
The DNA interactions of PT-BIS(ACRAMTU) ([Pt(en)-
(ACRAMTU)2](NO3)4; ACRAMTU = 1-[2-(acridin-9-
ylamino)ethyl]-1,3-dimethylthiourea, en = ethylene-
diamine),abifunctionalplatinum–acridineconjugate,
have been studied in native and synthetic double-
stranded DNAs and model duplexes using various
biophysical techniques. These include ethidium-
DNA fluorescence quenching and thermal melting
experiments, circular dichroism (CD) spectroscopy
and plasmid unwinding assays. In addition, the bind-
ing mode was studied in a short octamer by NMR
spectroscopy in conjunction with molecular model-
ing. In alternating copolymers, PT-BIS(ACRAMTU)
shows a distinct preference for poly(dA-dT)2,
which is  3-fold higher than that of ACRAMTU. In
the ligand-oligomer complex, d(GCTATAGC)2PT-
BIS(ACRAMTU) (complex I*), PT-BIS(ACRAMTU)
increases the thermal stability of the B-form host
duplex by DTm . 30 K (CD and UV melting experi-
ments). The agent unwinds pSP73 plasmid DNA by
44(62)  per bound molecule, indicating bisinter-
calative binding. A 2-D NMR study unequivocally
demonstrates that PT-BIS(ACRAMTU)’s chromo-
phores deeply bisintercalate into the 50-TA/TA base
pair steps in I*, while the platinum linker lies in the
minor groove. An AMBER model reflecting the
NMR results shows that bracketing of the central
AT base pairs in a classical nearest neighbor exclu-
ded fashion is feasible. PT-BIS(ACRAMTU) inhibits
DNAhydrolysisbyBstZ17Iattheenzyme’srestriction
site, GTA#TAC. Possible consequences for other
relevant DNA–protein interactions, such as those
involved in TATA-box-mediated transcription initi-
ation and the utility of the platinum-intercalator
technology for the design of sequence-specific
agents are discussed.
INTRODUCTION
Among the DNA binders, bisintercalating molecules have
attracted considerable attention in the bioorganic and drug
development communities (1,2). Bisintercalators consist of
two planar chromophores tethered by ﬂexible linker groups,
which are capable of simultaneously inserting into the DNA
base stack (3). Since the discoveryof echinomycin, a bioactive
natural product consisting of two quinoxaline chromophores
linked by a bicyclic peptide, bifunctional intercalating agents,
both natural and synthetic, have demonstrated promising
antimicrobial and antitumor properties (4). Several natural
products structurally related to echinomycin and synthetic
analogues have been studied for their biological activity
and DNA interactions, including agents such as luzopeptin (5),
TANDEM (6) and quinomycin (7). Motivated by the clinical
utility of these agents and the desire to understand the funda-
mental biophysical implications of bisintercalation, ‘simple’
bifunctional molecules, in which the peptidic linkages have
been replaced with polymethylene or polyamine chains, were
also designed. 9-Aminoacridine (9-AA) derivatives (8,9),
ethidium (10,11), thiazole orange (TO) (12) and naphtha-
limide (13) are some of the chromophores that have been
studied in great detail.
In a search for novel hybrid inorganic–organic molecules
for applications in cancer chemotherapy and transcription
regulation, we developed a new class of platinum-intercalator
conjugates based on the 9-aminoacridine derivative, 1-[2-
(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea (ACRAMTU,
acridinium salt, Figure 1) (14). PT-ACRAMTU ([PtCl(en)-
(ACRAMTU)](NO3)2,e n¼ ethylenediamine; Figure 1) and
its derivatives show promising activity in vitro in several solid
tumors, including ovarian and lung cancer cell lines (15–18).
While the cellular biology of the parent conjugate is still
under investigation, we proposed the unprecedented targeting
of adenine residues at 50-TA sites in the minor groove of DNA
by this dual metalating-intercalating agent (19,20) may play
an important role in its mechanism of action (21–23). Follow-
ing our interest in small-molecule modulators of transcription,
we have now begun to extend our studies to reversible
bifunctional intercalators derived from PT-ACRAMTU.
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scopies to probe the DNA interactions of the prototypical
conjugate, PT-BIS(ACRAMTU)([Pt(en)(ACRAMTU)2](NO3)4,
Figure 1). PT-BIS(ACRAMTU) is a cytotoxic agent shown
previously to strongly bind to native DNA with a binding
constant on the order of 10
7 M
 1 and an excluded site size
of n   4 bp, indicating the possibility of bisintercalative
binding (24). Our results presented here demonstrate that
this binding mode is, indeed, observed in the 50-TATA
sequence, which is known to play a crucial role in eukaryotic
transcription initiation (25). PT-BIS(ACRAMTU) emerges as
a structural motif that may offer a new approach to the design
of sequence-speciﬁc inhibitors of transcription.
MATERIALS AND METHODS
Drugs and biochemicals
PT-BIS(ACRAMTU) and ACRAMTU (nitrate salts) were
synthesized as described previously (15,24). Biochemical
grade chemicals (Fisher/Acros and DNase-free) available
were used for the preparation of biological buffers. All buffers
were made from doubly distilled 0.22 mm-ﬁltered DNase/
RNase-free water obtained from a Milli-Q A10 synthesis
water puriﬁcation system. All other chemicals were purchased
from common vendors and used without further puriﬁcation.
Stock solutions of PT-BIS(ACRAMTU) and ACRAMTU
were stored at 277 K in the dark. Buffered solutions of
oligodeoxyribonucleotide-ligand complex were lyophilized
and stored at 253 K.
DNA
The oligodeoxyribonucleotides (ODNs) were purchased from
Integrated DNA Technologies Inc. (Coralville, IA). All ODN
sequences were synthesized using phosphoramidite chemistry
and desalted by the vendor. The oligomer used in the NMR
study and in circular dichroism (CD) and thermal melting
experiments was further puriﬁed by size-exclusion chromato-
graphy (BioRad Biospin columns, Sephadex G-10 resin) and
dialyzed at 277 K for 72 h against 10 mM phosphate buffer
(pH 7.0) (Spectra/Por Float A Lyzer, 500 Da molecular weight
cut-off). Oligomer purity was conﬁrmed by
1H NMR spectro-
scopy (500 MHz). The synthetic 40mers used in the restriction
enzyme cleavage assay were puriﬁed by high-performance
liquid chromatography (HPLC) by the vendor. Quantiﬁcation
of ODNs was done spectrophotometrically in the appropriate
buffers at 260 nm using the molar absorptivities provided by
the vendor. Calf thymus DNA (lyophilized powder, Sigma)
and the synthetic alternating copolymers poly(dG-dC)2 and
poly(dA-dT)2 (Pharmacia Amersham Biotech) were used as
supplied. DNA concentrations (base pairs) were determined
from absorbances at 260 nm using Beer’s law with e260
(calf thymus) ¼ 12824 M
 1cm
 1 (bp), e260 (GC) ¼
16800 M
 1cm
 1 (bp) and e260 (AT) ¼ 13100 M
 1cm
 1
(bp) (26). DNA stock solutions were stored at 277 K. Plasmid
DNA (pSP73, 2464 bp) was isolated from transformed
Escherichia coli Nova-blue cells using a Qiagen plasmid
puriﬁcation kit.
Fluorescence quenching assay
All measurements were performed in 1 cm quartz cuvettes at
ambient temperature on a Perkin Elmer LS50B luminescence
spectrometer. Calf thymus DNA, poly(dG-dC)2 and poly(dA-
dT)2 were dissolved in a buffer containing 10 mM NaH2PO4,
0.1 mM Na2EDTA and 500 mM NaCl (pH 7.0) and annealed
by slow cooling from 348 K to room temperature. Stock solu-
tions of PT-BIS(ACRAMTU) (500 mM) and ACRAMTU
(80 mM) were prepared in the same buffer. Quenching of
ethidium-DNA ﬂuorescence was studied according to a pub-
lished assay (26). Samples (2000 ml) of ethidium-modiﬁed
native and synthetic DNAs (30.0 mM of DNA (bp) and
5.0 mM of ethidium bromide) were titrated with suitable ali-
quots of the drug solutions. Samples were mixed thoroughly
and equilibrated for 2 min before data acquisition. DNA-
bound ethidium was excited at 505 nm (slit width 10 nm),
and the ﬂuorescence intensity was monitored at 603 nm (slit
width 15 nm). PT-BIS(ACRAMTU) and ACRAMTU did not
ﬂuoresce at the emission of ethidium. The reported C50 values
(concentration of drug required to reduce the initial ethidium
ﬂuorescence by 50%) were calculated from plots of dilution-
corrected,normalizedﬂuorescenceintensitiesversusdrugcon-
centration using exponential curve ﬁts (Origin 7, OriginLab,
Northampton, MA). Reported values are averages of two
titrations.
Titrations and sample preparations
The oligonucleotide 50-GCTATAGC-30 (sequence I) was dis-
solved in 1 ml of sodium phosphate buffer [10 mM NaH2PO4
and 10 mM NaCl (pH 7.0)]. The sequence was annealed by
slow cooling from 348 K to room temperature and lyophil-
ized. The DNA ligand complex, d(GCTATAGC)2·PT-BIS-
(ACRAMTU) (I*) was generated by titrating suitable aliquots
of a saturated solution of PT-BIS(ACRAMTU) in D2Ot o
sequence I. Titrations were performed at 308 K in a 5 mm
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Figure 1. Structures of PT-BIS(ACRAMTU) and related complexes and
sequence I giving atom and residue numberings.
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1H NMR spectrum was recorded after each
addition. Integration of the H2/H7 signal of acridine and
thymine methyl protons was used to establish a 1:1 ligand-
to-duplex ratio. The complex (I*) was lyophilized twice from
99.96% D2O and ﬁnally dissolved in 500 ml of 99.96% D2O
to afford a concentration of  4 mM. The pH* (uncorrected
pH meter reading) of the solution was 7.0 7.1. Solutions of I
and I* for thermal melting and CD studies were prepared from
the NMR sample by appropriate dilution. For NMR experi-
ments at elevated temperatures, the samples were supplemen-
ted with additional NaCl to produce a total concentration of
0.1 M in Na
+.
Optical studies of thermal denaturation
Melting experiments for the free oligomer 50-GCTATAGC-30
(I) and complex I* were carried out in phosphate buffer
[10 mM NaH2PO4 and 10 mM NaCl (pH 7.0)]. Samples were
annealed by slow cooling from 348 K to room temperature
before data collection. The melting proﬁles were recorded
on an HP 8453 diode array spectrophotometer equipped
with a Peltier temperature-controlled cell-holder unit and an
external temperature probe. Quartz cells with 1 cm path length
were used in all experiments. Oligomer concentrations were
maintained at 7 mM and 3.5 mM for I and I*, respectively.
Absorbance as a function of temperature was measured at
260 nm. The temperature was raised in 0.5 K increments,
and the stirred samples were allowed to equilibrate for
1 min at each temperature setting. Absorbance data for both
heating and cooling traces were collected in the temperature
range 293–343 K. Melting temperatures were determined
from ﬁrst derivatives of the melting curves and conﬁrmed
by ﬁtting the data to the baseline-corrected two-state helix-
coil transition model using Microcal Origin 7 (OriginLab
Corp., Northampton, MA). Reported values are averages of
three determinations.
CD spectropolarimetry
CD experiments were performed on an AVIV Model 215
spectrophotometer equipped with a thermoelectrically-
controlled cell-holder. Solutions of 50-GCTATAGC-30 (I)
and PT-BIS(ACRAMTU) were prepared in the same buffer
used for the melting experiments. Quartz cells with 1 cm path
length were used for all experiments. Oligomer concentrations
were 6.3 mM and 100 mM for CD spectra recorded in the UV
(220–325 nm) and UV-visible (300–500 nm) regions, respect-
ively. CD spectra were recorded at 298 K in 1 nm increments
with an averaging time of 2 s.
Plasmid unwinding
Plasmid DNA, pSP73 [176 mM (bp)], was incubated at
room temperature with varying concentrations of PT-
BIS(ACRAMTU) (0 24 mM) in TE buffer [10 mM Tris
and 1 mM EDTA (pH 7.5)] for 1 h in the dark. Unwinding
of DNA was monitored by an electrophoretic mobility shift
assay (EMSA) described previously (27). Gels were run at
room temperature for 2 3 h at 70 V, stained twice with eth-
idium bromide (1 mg/ml), destained with 1% MgCl2 solution,
and photo-documented using the ChemiDoc XRS imaging
system (BioRad Laboratories, Hercules, CA). Unwinding
angles were calculated from the following equation,
j ¼ 18s/rb(c), using the experimentally determined rb(c) val-
ues (drug-to-nucleotide ratios at which the drug completely
unwinds supercoiled plasmid). The superhelical density (s)
of the plasmid under the present experimental conditions
was  0.063, calculated on the basis of the known unwinding
angle for the site-speciﬁc 1,2 intrastrand cross-link formed by
cisplatin (28). The average rb(c) value was extracted from
plots of band intensities versus ligand concentration using a
parabolic curve ﬁt (Origin 7, Originlab, Northhampton, MA).
Band intensities were integrated with the Quantity One soft-
ware (version 4.4.1; BioRad, Hercules, CA). Incubations and
unwinding assays were performed in triplicates.
Acquisition and processing of NMR data
NMRspectrawereacquiredat500MHzonaBrukerDRX-500
spectrometer equipped with an inverse 3-channel Z-gradient
TBI probe and a variable-temperature unit. The spectral width
was5000Hz,andthecarrierfrequencywassettothefrequency
of the HDO signal for one-dimensional (1-D) spectra and two-
dimensional (2-D) data sets collected in D2O. A spectral
width of 12530 Hz was used for spectra recorded in 90%
H2O/10% D2O. The WATERGATE (water suppression by
gradient-tailored excitation) and jump-and-return techniques
(29) were used to suppress the (residual) water peak. Chemical
shifts(d,p.p.m.)werereferencedtointernal3-(trimethyl-silyl)-
1-propanesulfonic acid sodium salt (DSS) standard. 1-D and
2-D NMR data sets were acquired at various temperatures
in the range 278–328 K. 1-D
1H NMR spectra were recorded
with a total of 64 K data points, 16 transients, and a recycle
delay of 1 s. The time domain data were apodized with an
exponential window function using a line broadening of
0.3 Hz and then Fourier transformed. The g-COSY (gradient
correlation spectroscopy) experiments were performed with
2048 complex points in t2, 512 points in t1 and 32 transients
per t1 increment with a recycle delay of 1.5 s. 2-D NOESY
(nuclear Overhauser enhancement spectroscopy) spectra were
acquired with 2048 complex points in t2, 256 points in t1,
64 transients per t1 increment and a recycle delay of 2 s. The
mixing time (tm) was 350 ms. All data were multiplied with
optimized phase-shifted squared sinebell apodization func-
tions and zero-ﬁlled to a ﬁnal matrix of 2048 · 2048 data
points before Fourier transformation. 1-D spectra were pro-
cessed using the XWIN-NMR software (version 2.6, Bruker,
Ettlingen, Germany), and 2-D data sets were processed with
Felix 2000 (Accelrys, San Diego, CA) installed on a Silicon
Graphics O2 workstation.
Modeling
Calculations were performed using the AMBER force ﬁeld
in the InsightII/Discover software (version 2000, Accelrys,
San Diego, CA). Starting structures of the B-form octamer
d(GCTATAGC)2 (I) and PT-BIS(ACRAMTU) were built
using the Biopolymer module in InsightII. The duplex and
the drug were energy-minimized separately, followed by
‘manual’ docking of the bisintercalator into the minor groove.
To guide the drug’s chromophores into the T3A6/T5A4 base
pair steps, the following intermolecular drug-DNA distance
restraints using a simple quadratic harmonic were initially
included in the minimizations: ACRH3   T5CH3,
ACRH4   T5CH3, ACRH5   T3CH3, and ACRH6   T3CH3,
5624 Nucleic Acids Research, 2005, Vol. 33, No. 17with d ¼ 3.0 A ˚, based on the medium cross-peak intensities
observed in the NOESY spectra, and force constants in the
range 10–100 kcal mol
 1 A ˚  2. Sodium (+1) counter ions were
used to balance the negative charge of the DNA phosphate and
solvent was simulated with a distance-dependent dielectric
(e ¼ 4rij). Coulombic and 1 4 parameters were scaled by a
factor of 0.5. Atom types, force constants, equilibrium bond
lengths and angles, and charge distribution schemes were
adopted from previous modeling studies of ACRAMTU and
PT-ACRAMTU (19,30). Ad hoc parameters for the drug
molecule were optimized to most accurately reproduce
the structure of PT-BIS(ACRAMTU) in the solid state.
(Details of the crystal structure of PT-BIS(ACRAMTU)
([Pt(N2C2H8)(C18H21N4S)2]Cl4·9H2O) used to validate the
force ﬁeld have been deposited with the Cambridge Crystal-
lographic Data Centre as Supplementary publication no.
CCDC 268383. Copies of the data can be obtained free of
charge from the CCDC; 12 Union Road, Cambridge CB2 1EZ,
UK; http://ccdc.cam.ac.uk.) The drug-DNA complex (I*) was
subjected to steepest descent and conjugate gradient minim-
izationuntilthe convergencecriteriaofDrms0.001kcalmol
 1
A ˚  1 was satisﬁed. Molecular views of the model were gen-
erated from car ﬁles using DS ViewerPro (version 6.0,
Accelrys, San Diego, CA).
Restriction enzyme cleavage assay
Stock solutions of the drugs and the single-stranded ODNs,
50-GGCACGTGGAACTCTGGGTATACTCAGCGAGGCC-
TACTCAGCGAGGCCGGCCTC-30 (‘top strand’) and 50-
GAGGCCGGCCTCGCTGAGTATACCCAGAGTTCCACG-
TGCC-30 (‘bottom strand’), were preparedin10mM Tris–HCl
buffer (pH 7.5) and stored at 253 K in the dark until used.
Concentrations of drugs and ODNs were determined spectro-
photometrically. The top strand of the probe was labeled at
the 50 end using T4 polynucleotide kinase (EPICENTRE
Biotechnologies, Madison, WI) and [g-
32P]ATP (Amersham
Biosciences, Piscataway, NJ). Top and bottom strands were
annealed in 50 mM NaCl by incubating both strands at 368 K
for 5 min, followed by slow cooling to room temperature in a
dry bath. Radiolabeled probe samples were puriﬁed using
Sephadex G-25 Quick Spin Columns (Roche, Indianapolis,
IN). The labeled probe (0.1 mM) was incubated at room
temperature with PT-BIS(ACRAMTU) and ACRAMTU
(0–100 mM), and the mixtures were allowed to equilibrate
for 30 min. Drug-modiﬁed and unmodiﬁed probe samples
were then allowed to react with 7.5 U of the restriction enzyme
BstZ17 I (New England Biolabs, Beverly, MA) at 310 K for
45 min in enzyme buffer provided by the vendor. Reaction
products were analyzed by PAGE under denaturing conditions
(12% acrylamide, 8 M urea; SequaGel Sequencing System,
National Diagnostics, Inc.). Electrophoretic separations were
carried out at 190 V for 1 h, and the dried gels were analyzed
on a BioRad FX-Pro Plus phosphorimager (Hercules, CA).
RESULTS
Biophysical characterization of the binding mode
DNA-ethidium ﬂuorescence assays are a useful tool for
studying the binding afﬁnity and global sequence selectivity
of DNA binders. In these assays, the quenching is monitored
by ﬂuorescence originating from DNA-bound ethidium, which
results from displacement of the chromophore by a competing
ligand and/or direct contact between the reporter and probe
ligands co-occupying the biopolymer (31). In the present
study, the binding afﬁnity of PT-BIS(ACRAMTU) to native
DNA and synthetic alternating AT and GC copolymers was
determined. The titrations were performed at neutral pH to
ensure that acridine was present in its protonated form, and
high-salt conditions (500 mM NaCl) were applied to reduce
non-speciﬁc binding of the highly charged (4+) agent.
ACRAMTU was included in this study to allow for a direct
comparison between the effects of mono- and bisintercalation
under the speciﬁc experimental conditions. The ﬂuorescence
data are plotted in Figure 2. The C50 values (concentration of
acridine effecting 50% quenching of the ethidium ﬂuores-
cence) are given in Figure 2 caption. Based on ﬂuorescence
quenching efﬁciencies, the order of binding afﬁnities of
PT-BIS(ACRAMTU) was found to be poly(dA-dT)2 > calf
thymus DNA > poly(dG-dC)2. While an  4-fold higher afﬁn-
ity is observed in the alternating AT sequence compared to the
GCsequence,the agentshowsintermediateafﬁnitytorandom-
sequence DNA. In poly(dA-dT)2, PT-BIS(ACRAMTU)
reduces the ethidium ﬂuorescence to a greater extent than
ACRAMTU (Figure 2), as can be expected for the increased
number of chromophores and ‘bite size’ of a bifunctional
molecule compared to a simple monointercalator. Surpris-
ingly, the reverse situation is observed in poly(dG-dC)2,
where PT-BIS(ACRAMTU) proves to be an even less efﬁcient
quencher than ACRAMTU (Figure 2). These ﬁndings may
indicate that a bisintercalative binding mode is disfavored
in alternating GC sequences. In essence, the linking of two
ACRAMTU units in PT-BIS(ACRAMTU) leads to an  3-fold
increase in AT selectivity, based on C50(GC)/C50(TA) ratios
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Figure 2. DNA-ethidium fluorescence monitored at 603 nm in the presence of
varying concentrations of intercalating agents (numbers in parentheses are C50
[mM] values). Squares: PT-BIS(ACRAMTU)/poly(dA-dT)2 (17.72); triangles:
PT-BIS(ACRAMTU)/calfthymusDNA(32.65);circles:PT-BIS(ACRAMTU)/
poly(dG-dC)2 (65.14); solid line: ACRAMTU/poly(dA-dT)2 (40.54); dashed
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shown for ACRAMTU.
Nucleic Acids Research, 2005, Vol. 33, No. 17 5625of 3.7 and 1.3 for PT-BIS(ACRAMTU) and ACRAMTU,
respectively.
While the results of the ﬂuorescence quenchingexperiments
indicate that PT-BIS(ACRAMTU) binds to alternating AT
most likely through bisintercalation, the exact site and
mode of binding remained to be elucidated. Simple molecular
models suggested that a conformation of PT-BIS(ACRAMTU)
exists in which the two chromophores are coplanar to one
another and separated by  10 A ˚, suitable for bracketing
2 bp in a bisintercalative binding mode. Previous studies of
ACRAMTU and PT-ACRAMTU have shown that both agents
intercalate into the 50-TA step preferentially from the minor
groove (21,30). To gain further insight into the binding pref-
erence within AT sequences we performed equilibrium
dialysis experiments (see Supplementary Data) using short
model duplexes as described previously for ACRAMTU (30).
The results indicate that PT-BIS(ACRAMTU) binds to the
50-TATA and 50-ATAT sequences with similar afﬁnity,
whereas binding to 50-AATT is clearly disfavored. This
supports the notion that the two former sequences may be
target sites for the proposed mode of bisintercalation of PT-
BIS(ACRAMTU), in accordance with the classical sequence
requirements of intercalation (32). Given the biological
relevance of the 50-TATA site, further biophysical and high-
resolution structural work was performed using the sequence,
50-GCTATAGC-30 (I) (Figure 1). Similarly, a 40 bp probe
containing the TATA site was used in the restriction enzyme
cleavage assay (Figure 9).
UV melting proﬁles were recorded of sequence I alone and
in the presence of one equivalent of PT-BIS(ACRAMTU)
(Figure 3). In our experiments, which used an oligomer
concentration of 7 mM and a buffer containing 20 mM Na
+,
the unmodiﬁed sequence I was found to melt below 293 K.
The theoretical melting temperature estimated for this
oligomer is 294(±2) K (33). Addition of one equivalent of
PT-BIS(ACRAMTU) (monitored by
1H NMR spectroscopy,
see Materials and Methods section) to form the 1:1 complex,
d(GCTATAGC)2·PT-BIS(ACRAMTU) (I*), causes a dram-
atic increase in the thermal stability of the duplex. Complex I*
was found to melt at 326.6 K, indicating an unusual DTm
of greater than 30 K. Under similar experimental conditions
ACRAMTU increases the melting temperature of similar
oligomer duplexes only insigniﬁcantly (DTm   2 K) (34).
It is noteworthy to mention that PT-BIS(ACRAMTU) affects
the thermal melting behavior of extended duplexes that are
prone to hairpin formation. In d(GGTGGTATACCACC)2, for
instance, PT-BIS(ACRAMTU) appears to completely elimin-
ate the biphasic melting of the self-complementary duplex,
which in its unmodiﬁed form shows distinct duplex ! hairpin
and hairpin ! random coil transitions (35). These ﬁndings
suggest that PT-BIS(ACRAMTU) stabilizes the duplex form
through bisintercalation into the central (TATA)2 sequence,
which is supported by the equilibrium dialysis experiments
(see Suplementary Data).
The CD spectrum recorded of the modiﬁed duplex (I*)
in the 200–320 nm region, which is dominated by the CD
of the DNA base pairs, shows a signal characteristic of a
B-form helix with a negative band at 254 nm and a positive
band at 275 nm (Figure 4a) (36). A comparison with the same
feature in unmodiﬁed I suggests that PT-BIS(ACRAMTU)
causes a conformational change in the oligomer structure
upon binding, as evidenced by both the increase in band amp-
litudes and a pronounced blue-shift of the positive band by
7 nm. An explanation for the distinct shift of this CD band
cannot be given at this point. In the 300–500 nm region of the
CD spectrum of I*, a feature resulting from induced circular
dichroism (ICD) is observed (Figure 4b). The ICD is the result
of dipole–dipole interactions between the base pairs of the
chiral duplex and the intercalated chromophores of intri-
nsically CD-inactive PT-BIS(ACRAMTU). The positive
sign, amplitude and shape of the ICD are indicative of a
bisintercalative binding mode, in which the long axes of the
acridine chromophores are collinear with the long dimensions
of the base pair pockets (37). However, the ICD of duplex-
bound PT-BIS(ACRAMTU) does not resemble the absorp-
tion spectrum of acridine, implying that the alignment of
the chromophores with adjacent base pairs deviates some-
what from that observed in DNA complexes of monomeric
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Figure 3. UV melting profile monitored at 260 nm for complex I*. The inset shows the melting trace recorded for the unmodified sequence, I. Experiments were
performed at octamer concentrations of 3.5 and 7.0 mM, respectively [10 mM phosphate and 10 mM NaCl (pH 7.0)].
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for instance, has been shown to mimic the UV-visible features
of the acridine chromophore (34).) This deviation is most
likely caused by the rigidity produced by the [Pt(en)] linkage
connecting the two ACRAMTU molecules in the conjugate.
To discriminate between monofunctional and bifunctional
intercalation, the ability of PT-BIS(ACRAMTU) to remove
and reverse the supercoils in closed-circular pSP73 plasmid
DNA was assessed by an EMSA (38). The negatively super-
coiled plasmid was modiﬁed with varying concentrations of
PT-BIS(ACRAMTU), and the samples were run on agarose
gels. Figure 5 shows a representative gel resulting from
a DNA-ligand titration. With increasing concentration of
PT-BIS(ACRAMTU), supercoils in the plasmid are gradually
removed until the DNA exists in its relaxed open-circular
form. From the ligand-to-nucleotide ratio at which the
relaxed form comigrates with the (naturally present) nicked
open-circular form, rb(c) ¼ 0.026(2), and the superhelical
density ofthe plasmid(see Materials andMethods) anunwind-
ing angle of 44(±2)  per bound molecule was determined.
For comparison, under similar conditions, monointercalating
PT-ACRAMTU has been shown to unwind DNA by 21 
(19,27). Thus, it can be rationalized that the efﬁcient unwind-
ing of DNA by PT-BIS(ACRAMTU) is the result of simul-
taneous intercalation of both of its acridine chromophores.
Unwinding angles of similar magnitude have been reported
recently for a series of bis(acridinecarboxamides) (39).
High-resolution structural study
To gain insight into the DNA binding mode of PT-
BIS(ACRAMTU) in complex I* at the molecular level, a
2-D NMR study was performed, and an AMBER model
was generated based on the combined NMR data. Several
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Figure 5. Unwinding of supercoiled pSP73 plasmid by PT-BIS(ACRAMTU). With increasing concentration of PT-BIS(ACRAMTU), relaxation of negatively
supercoiled plasmid (sc) occurs resulting in the open-circular form (oc), as indicated by the change in electrophoretic mobility of the plasmid. At higher
concentrations, PT-BIS(ACRAMTU) induces positive supercoils, thereby increasing the mobility of the modified plasmid. Drug-to-nucleotide ratios (rb) for lanes
1–14 are 0 (control), 0.011, 0.014, 0.017, 0.019, 0.022, 0.025, 0.028, 0.031, 0.034, 0.037, 0.045, 0.056 and 0.068 respectively.
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1H NMR spectra
recorded during the titration of sequence I with one equivalent
of drug suggested that the central 50-TATA site is indeed
involved in complex formation. Upon addition of PT-
BIS(ACRAMTU), the A4H8 and A6H8 signals disappear
and a new set of signals appears shifted upﬁeld by
 0.2 p.p.m.. Likewise, the signals assigned to T3CH3 and
T5CH3 experience a distinct downﬁeld shift of similar mag-
nitude. In addition, a new set of broad signals is observed for
PT-BIS(ACRAMTU). The change in line shapes during the
NMR titrations indicated that complex I* is in intermediate
chemicalexchange(40),andunambiguousprotonassignments
from data sets acquired at 298 K proved to be unfeasible due
to severe signal broadening. A similar dynamic behavior was
observed previously for complexes of ACRAMTU (30). The
observation that only one new set of signals is observed
during the titration until a 1:1 duplex-to-bisintercalator stoi-
chiometry is reached indicates that the drug binds site-
speciﬁcally, which was conﬁrmed by 2-D NMR experiments
(vide infra). No further attempts were therefore made to
investigate ligand-to-duplex ratios >1 for potential secondary
binding sites. Variable-temperature
1H NMR spectra
(Supporting Information) of I* recorded in the range 298–
328 K indicate that with increasing temperature the line widths
could be reduced and the signals resolved without com-
promising the stability of the duplex. In spectra recorded at
328 K in 90% H2O/10% D2O (not shown) the signals of the
imino protons involved in interstrand hydrogen bonding were
clearly observable, corroborating that the duplex was still
intact. Thus, we took advantage of the unusual thermal sta-
bility of complex I* and acquired the 2-D NMR data sets at
elevated temperatures.
Routine strategies using 2-D NOESY and (magnitude)
COSY spectra were applied to assign the non-exchangeable
protons of the oligomer (Supplementary Table S1) and the
protonsofthedrug(Supplementary Table S2).Theassignment
of the base and deoxyribose protons was accomplished using
both H10(i-1) ! H8/H6(i) and H20/H200(i-1) ! H8/H6(i)
sequential NOE contacts (41). The section of the 2-D
NOESY spectrum of I* depicted in Figure 6a shows that
the ‘NOE walk’ is interrupted between T3H20 and A4H8
and between T5H20 and A6H8, as indicated by the complete
absence of the corresponding cross-peaks. This important
feature and the fact that a strong internucleotide cross-peak
is observed for A4H8   T5CH3 (Figure 5a) is consistent
with sequence-speciﬁc bisintercalation of the acridine chro-
mophores into the 50-T3A4/T5A6 base pair steps of the
C2-symmetric duplex (Figure 6b). This contrasts the binding
of ACRAMTU, which did not cause disruption of sequential
NOE connectivities due to rapid association/dissociation
(‘on/off’) rates and exchange between multiple sites (30).
The aromatic protons of the acridine chromophores, H1–
H8, appear signiﬁcantly upﬁeld shifted by as much as
0.8 p.p.m. relative to those in the unbound drug due to the
ring current effect of the stacked DNA bases. On the other
hand, H10–H12 of the linker in bound PT-BIS(ACRAMTU)
are downﬁeld shifted by the opposite ring current effect of
the base pair edges (Supplementary Table S2). These ﬁndings
are consistent with an intercalative binding mode of the planar
acridine rings (42), while indicating extrahelical (groove)
binding of the platinum thiourea moiety (30).
At the site of intercalation, the aromatic acridine protons
H1–H8 make NOE contacts with the H20/H200 deoxyribose
protons of both strands. This observation is consistent with
an intercalation geometry in which the drug’s chromophores
are aligned with the long dimensions of the base pairs deﬁning
the intercalation pocket. The NOESY spectrum also contains
a wealth of information about the regioselectivity of the bis-
intercalation mode. Strong NOE cross-peaks are observed
between H3–H6 of the acridine moieties and the thymine
methyl groups (T3CH3 and T5CH3), which indicates PT-
BIS(ACRAMTU)’s chromophores efﬁciently penetrate the
host duplex from the minor groove. This notion is further
supported by NOE contacts observed between the thiourea
methyl groups (C11) and the H10/H40 deoxyribose protons
adjacent to the intercalation sites (Figure 6c), conﬁrming
that the platinum linker makes close contact with the walls
of the minor groove. Crucial intermolecular and interresidue
NOE contacts at the drug binding site are summarized in
Figure 7.
A strain-minimized AMBER model of complex I* was
generated that reﬂects the results of the NMR study
(Figure 8). In this model, the duplex accommodates bis-
intercalating PT-BIS(ACRAMTU) without major helical dis-
tortions and disruption of Watson–Crick hydrogen bonding.
The rise at the T3A4/T5A6 base pair steps, however,
has doubled to allow insertion of the two drug chromo-
phores. The semirigid platinum–thiourea linker in PT-
BIS(ACRAMTU) is positioned in the minor groove and
produces the appropriate ‘bite’ to allow strainless bracketing
of the two central AT base pairs. The binding mode produces
short hydrophobic contacts between the linker and the walls
of the minor groove. While the platinum-ethylenediamine
moiety is directed away from the helical axis, the thiourea
sulfur atoms make van der Waals contact with the edges
of the central adenine residues at the bottom of the minor
groove. This tight association allows deep penetration of
PT-BIS(ACRAMTU)’s planar moieties into the base stack,
concomitantly producing close contacts between the chromo-
phores and the thymine methyl groups in the major groove.
Restriction enzyme inhibition
To investigate the effect of DNA-bound PT-BIS(ACRAMTU)
on DNA-processing enzymes, a restriction enzyme cleavage
assay was performed. BstZ17 I is a restriction endonuclease
that produces a blunt-end cut in the recognition sequence,
GTA#TAC, where the arrow marks the site of hydrolytic
cleavage. This restriction site was chosen because it contains
the sequence 50-TATA, a proposed target site for PT-
BIS(ACRAMTU). Bisintercalation of PT-BIS(ACRAMTU)
into this sequence can be expected to reduce the DNA-
cleaving ability of the enzyme by conformational changes
within the recognition site or by steric blockage. The 40 bp
probe designed for this study containing a central GTATAC
palindromic sequence is shown in Figure 9. PAGE analysis
under denaturing conditions was used to monitor the cleavage
of the probe by BstZ17 I in the presence of mono- and bisin-
tercalator. Titration of the probe with PT-BIS(ACRAMTU)
leads to virtually complete inhibition of endonucleolytic
cleavage at a ligand concentration of 25 mM, as evidenced
by the disappearance of the high-mobility band resulting
5628 Nucleic Acids Research, 2005, Vol. 33, No. 17from the 20 bp labeled fragment of the cleaved top strand. In
contrast,ACRAMTU showedno effect,even atconcentrations
as high as 100 mM (Figure 9). These results suggest that
bisintercalation, but not monointercalation, into the 50-
TATA sequence protects the probe duplex from cleavage at
the central 50-AT/AT base pair step of the restriction site.
DISCUSSION
The current study provides insight into the mechanism of
action at the DNA level of PT-BIS(ACRAMTU). Our results
suggest that bisintercalative binding, a potentially cytotoxic
lesion in genomic DNA of this agent, is feasible and prefer-
entially occurs in alternating TA sequences. Unlike the parent
compound PT-ACRAMTU (20–22), PT-BIS(ACRAMTU)
does not induce adducts with nucleobase nitrogen but binds
to DNA in a reversible manner. (The inability of sulfur-bound
ACRAMTU to act as a leaving group in reactions with double-
stranded DNA has been amply demonstrated (21).) PT-
BIS(ACRAMTU) shows a unique mode of bisintercalation
that is more efﬁcient in discriminating between AT and GC
sequences than monointercalation by ACRAMTU (27). In the
model complex d(GCTATAGC)2·PT-BIS(ACRAMTU) (I*),
the drug associates tightly with the TATA sequence, a poten-
tial target site, through combined minor groove binding and
bisintercalation, which leads to a pronounced increase in the
thermal stability of the duplex. The platinum–thiourea linker
aligns perfectly with the minor groove’s curvature, providing
the correct spacing betweenthe two acridine chromophoresfor
classical nearest neighbor excluded bisintercalative binding.
The combined NMR and modeling results suggest that tight
‘clamping’ of the central AT/AT step and deep penetration of
the base stack by the acridine chromophores in complex I*
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Figure 6. 2-D NOESY study of the drug–octamer complex I* [500 MHz, 328 K, tm ¼ 350 ms, buffer: D2O, 10 mM phosphate (pH* 7.0) and 90 mM NaCl].
(a) Section of the 2-D NOESY spectrum showing sequential connectivities in the aromatic-H20/H200 region (solid lines). Absent cross-peaks due to disruption of
theT3H20-A4H8andT5H20-A6H8interresidueNOEsare indicatedbyarrows.Thedashedverticallineindicatesthe connectivitybetweenA4H8andT5CH3at the
central base pair step. Assignment of intermolecular cross-peaks: (A) A4,A6H20/H200-ACRH2/H7; (B) T3H200-ACRH7; (C) T5H200-ACRH2; (D) T3H20-ACRH7;
(E) T3CH3-ACRH7; (F) T3H20-ACRH6; (G) A6H20/H200-ACRH1; (H) T5H200-ACRH1; (I) T3CH3-ACRH5 and T3CH3-ACRH6. The cross-peak for T5CH3-
ACRH5 is partially overlapped with the intranucleobase cross-peak, T5CH3-T5H6 (top of the two cross-peaks connected by dashed line). (b) Illustration of the
intercalation mode leading to interruption of the NOE connectivities at the 50-T3A4/T5A6 base pair steps. (c) Section of the 2-D NOESY spectrum showing cross-
peaks due to NOE contacts between the thiourea methyl groups (C11) and H10 and H40 deoxyribose protons in the minor groove of the octamer. Cross-peak
assignments: (A) A4H10-ACRH11; (B) A6H10-ACRH11; (C) T3H10-ACRH11; (D) T5H10-ACRH11; (E) A6H40- ACRH11.
Nucleic Acids Research, 2005, Vol. 33, No. 17 5629produces hydrophobic interactions between the drug and
the minor groove. We believe the steric clash observed in
computer models (not shown) at an analogous GC/GC step
between the exocyclic NH2 group of guanine in the minor
groove and thiourea sulfur may hinder insertion of the chro-
mophores. This would explain the reduced binding afﬁnity
observed in poly(dG-dC)2.
The concept of linking two (or multiple) intercalators in a
single molecule was inspired by the possibility of generating
agents with greater DNA afﬁnity and DNA structural impact
compared to the corresponding monointercalators (2). Bisin-
tercalation typically occurs with a minimum of one base pair
step remaining vacant between intercalation sites, as implied
by the nearest neighbor exclusion principle (43), and leads to
local unwinding and lengthening of the host duplex (32).
These structural distortions presumably interfere with DNA-
processing enzymes to disrupt processes vital to cell function
and proliferation, such as transcription and replication. The
mechanism by which PT-BIS(ACRAMTU)’s DNA damage
is recognized and the enzymes and DNA binding proteins
involved in its processing remain to be determined. Recently,
several new classes of anticancer active bisintercalators
based on acridine- and phenazine-4-carboxamides have been
described that target the cancer cell’s polymerase and topoi-
somerase enzymes (39,44,45). These studies demonstrate that
the speciﬁc signaling pathways through which these agents
induce cancer cell death are not easily resolvable. Structure-
activity relationship (SAR) studies of DNA-threading bisac-
ridines show that tuning of the lifetimes of the intercalated
state and the degree of duplex unwinding may alter the cell
kill mechanism (39). These issues remain to be addressed in
the case of PT-BIS(ACRAMTU) and its derivatives.
A recent study (46) shows that ‘covalent’ adducts formed by
PT-ACRAMTU in the minor groove of a TATA box sequence
inhibit the binding of human TATA-binding protein (hTBP).
hTBP, which associates with its cognate sequence, TATA(A/
T)A(A/T)N (N stands for any residue), through the DNA
minor groove (47), is a key component of the transcription
*GGCACGTGGAACTCTGGGTATACTCAGCGAGGCCGGCCTC
CCGTGCACCTTGAGACCCATATGAGTCGCTCCGGCCGGAG
[PT-BIS(ACRAMTU)] [ACRAMTU]
C 1 C 211 02 55 05 0 1 0 0 µ µ µ µM
f.l.
cl.
[PT-BIS(ACRAMTU)] [ACRAMTU]
C 1 C 211 02 55 05 0 1 0 0 µ µ µ µM
f.l.
cl.
Figure 9. Restrictionenzyme-mediatedcleavagebyBstZ17Iofa40bpduplex
modified with PT-BIS(ACRAMTU) or ACRAMTU monitored by denaturing
PAGE. Control lanes labeled C1 and C2 contain unmodified probe with no
enzymeaddedandunmodifiedprobecleavedwithenzyme,respectively.Bands
are labeled ‘f.l.’ for full-length and ‘cl.’ for cleaved probe. The sequence of
the probe is shown with the blunt-end restriction site highlighted in bold. The
asterisk denotes the
32P-labeled 50 end, and the arrows indicate the sites of
hydrolytic cleavage.
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Figure 8. View into the majorgroove of anenergy-minimized AMBERmodel
ofduplexI* basedon NMRdata. Theoligomeris shownin green,andthe drug
molecule is represented by CPK rendering. The thymine methyl groups are
highlighted as space-filling spheres.
5630 Nucleic Acids Research, 2005, Vol. 33, No. 17initiation complex (48). Thus, it was argued that platinum
adducts, if formed at a high frequency in the promoter regions
of genomic DNA, can be expected to down-modulate
transcription, potentially contributing to the cytotoxicity of
PT-ACRAMTU. In this study we have demonstrated the
ability of PT-BIS(ACRAMTU) to inhibit endonucleolytic
DNA cleavage, most likely by binding of the bisintercalator
to the enzyme’s TATA-containing restriction site. We suggest
that strong reversible association of PT-BIS(ACRAMTU)
(and suitably modiﬁed derivatives with enhanced DNA
afﬁnity) with TATA box sequences may produce similar
effects. An important aspect of the DNA binding mode estab-
lished in this study is related to our endeavors to design
sequence-speciﬁc modulators of transcription using the plati-
num intercalator technology. Unfortunately, PT-ACRAMTU
lacks long-range sequence speciﬁcity and has been shown to
promiscuously (and irreversibly) bind to nucleophilic sites
of adenine and guanine in both grooves of double-stranded
DNA, suggesting that this metalating agent may not be a good
candidate for targeting the minor groove of the TATA
sequence. In this regard, the PT-BIS(ACRAMTU) approach
appears to be more promising. Earlier, it was rationalized that
the increase in binding site sizes of bisintercalators compared
to their monomeric precursors might be a viable strategy for
producing agents with improved DNA binding selectivity
through enhanced sequence and groove read-out (2). While
the simple polymethylene- and polyamine-linked bisintercal-
ators show no signiﬁcant sequence speciﬁcity, recent work
by Dervan et al. (49) suggests that speciﬁc minor groove
recognition by designed polyamide linkers has the potential
of turning bisintercalators into gene-speciﬁc agents. Because
PT-BIS(ACRAMTU)’s high-afﬁnity sequence, 50-TATA, is
found in the promoter region of most genes transcribed by
eukaryotic RNA polymerase II (vide supra), our bisintercal-
ator approach may offer a unique way of targeting the tran-
scription machinery of speciﬁc genes. Naturally, this would
require structural modiﬁcation of the prototype to enhance its
DNA binding afﬁnity and to produce sequence speciﬁcity for,
and beyond, the 50-TATA tetranucleotide site. These studies
are currently underway.
SUPPLEMENTARY DATA
Supplementary data are available at NAR Online.
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